Bayer A sales and marketing update

The U.K.’s NICE issued final guidance recommending use of Xarelto rivaroxaban from Bayer in combination with aspirin plus clopidogrel or aspirin alone to prevent atherothrombotic events in patients who have acute coronary syndrome (ACS) with elevated cardiac biomarkers. The final guidance is in line with draft guidance issued last October and a final appraisal determination issued in January (see BioCentury, Oct. 27, 2014). ...